Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease
- 1 May 2021
- journal article
- editorial
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 32 (5) , 261-263
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2020
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicineEuropean Heart Journal, 2020
- Diabetic kidney diseaseNature Reviews Disease Primers, 2015
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney DiseaseJournal of the American Society of Nephrology, 2014
- The Multifaceted Mineralocorticoid ReceptorComprehensive Physiology, 2014
- Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in miceJournal of Clinical Investigation, 2010
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Mineralocorticoid receptor knockout mice: Pathophysiology of Na + metabolismProceedings of the National Academy of Sciences, 1998